Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 113

Sort by

Sort Order Select

Journal Articles

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Dominic Pizzarella, Amanda Kofides, Xia Liu, John Hatcher, Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Hao Sun, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Sirano Dhe-Paganon, Steven Treon, Shirong Liu

Blood (2025) 146 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2025-7453

Published: 2025

Journal Articles

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Zachary Hunter, Amanda Kofides, Abigail Peachey, Nickolas Tsakmaklis, Maria Luisa Guerrera, Xia Liu, Shirong Liu, Hao Sun, Alberto Guijosa, John Hatcher, Dominic Pizzarella, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2025-3544

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Nicholas Paciaroni, Nina Budano, Julia Nguyen, Kirsten Meid, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Zachary Hunter, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 5392.

https://doi.org/10.1182/blood-2025-5392

Published: 2025

Journal Articles

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

Jorge Castillo, Andrew Branagan, Gottfried von Keudell, Alberto Guijosa, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Nickolas Tsakmaklis, Zachary Hunter, Steven Treon, Shayna Sarosiek

Blood (2025) 146 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2025-1794

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Blood (2025) 146 (Supplement 1): 2332.

https://doi.org/10.1182/blood-2025-2332

Published: 2025

Journal Articles

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Alberto Guijosa, Nickolas Tsakmaklis, Margaret Kobs, Nina Budano, Julia Nguyen, Alexandra Eurell, Maria Luisa Guerrera, Gottfried von Keudell, Andrew Branagan, Zachary Hunter, Steven Treon, Shayna Sarosiek, Jorge Castillo

Blood (2025) 146 (Supplement 1): 3577.

https://doi.org/10.1182/blood-2025-3577

Published: 2025

Journal Articles

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

Shirong Liu, Xia Liu, Amanda Kofides, John Hatcher, Nickolas Tsakmaklis, Abigail Peachey, Dominic Pizzarella, Alberto Guijosa, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Steven Treon

Blood (2025) 146 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2025-2171

Published: 2025

Journal Articles

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe-Paganon, John Hatcher, Andres Ramirez, Dominic Pizzarella, Amanda Kofides, Abigail Peachey, Shirong Liu, Hao Sun, Xia Liu, Maria Luisa Guerrera, Andrew Branagan, Gottfried von Keudell, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2025-3611

Published: 2025

Journal Articles

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Shayna Sarosiek, Mary Kwok, Prashant Kapoor, Hannah Chory, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Alberto Guijosa, Nickolas Tsakmaklis, Zachary Hunter, Andrew Branagan, Steven Treon, Jorge Castillo

Blood (2025) 146 (Supplement 1): 581.

https://doi.org/10.1182/blood-2025-581

Published: 2025

Journal Articles

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Xia Liu, Shirong Liu, Amanda Kofides, Dominic Pizzarella, Jinhua Wang, Sara Buhrlage, Nickolas Tsakmaklis, Abigail Peachey, Alberto Guijosa, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, John Hatcher, Steven Treon

Blood (2025) 146 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2025-5324

Published: 2025

Journal Articles

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Blood (2025) 146 (Supplement 1): 225.

https://doi.org/10.1182/blood-2025-225

Published: 2025

Journal Articles

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, Andres Ramirez, Amanda Kofides, Abigail Peachey, Xia Liu, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 224.

https://doi.org/10.1182/blood-2025-224

Published: 2025

Journal Articles

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, Anil Aktas Samur, Zachary Hunter, Masood Shammas, Jill Corre, Mariateresa Fulciniti, Kenneth C. Anderson, Giovanni Parmigiani, Steven P. Treon, Mohamad Mohty, Nikhil C. Munshi, Mehmet Kemal Samur

Blood (2021) 138 (20): 1980–1985.

https://doi.org/10.1182/blood.2021011452

Published: 2021

Includes: Supplemental data

Journal Articles

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Joshua Gustine, Kirsten Meid, MPH, Patricia Severns, NP, Toni Dubeau, NP, Nickolas Tsakmaklis, BA, Christopher Patterson, MAcc, Guang Yang, PhD, Xia Liu, MD, Maria Demos, BS, Amanda Kofides, BS, Jiaji Chen, BS, Manit Munshi, MS, Maria Luisa Guerrera, MD, Gloria Chan, MS, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MDPhDFRCP, Lian Xu

Blood (2017) 130 (Supplement 1): 5140.

https://doi.org/10.1182/blood.V130.Suppl_1.5140.5140

Published: 2017

Journal Articles

Somatic Variants Associated with MDS/AML Are Present in MYD88 Mutated Waldenstrom's Macroglobulinemia

Gloria Chan, MS, Joshua Gustine, Nickolas Tsakmaklis, BA, Lian Xu, Amanda Kofides, BS, Maria Demos, BS, Steven P Treon, MDPhDFRCP, Zachary Hunter, PhD

Blood (2017) 130 (Supplement 1): 4983.

https://doi.org/10.1182/blood.V130.Suppl_1.4983.4983

Published: 2017

Journal Articles

Characterization of Chromosome 6q Deletions in MYD88 Mutant and Wild-Type Waldenström's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 4984.

https://doi.org/10.1182/blood.V130.Suppl_1.4984.4984

Published: 2017

Journal Articles

PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Na Li, MD, Mariateresa Fulciniti, PhD, Michael A Lopez, BS, Tommaso Perini, MD, Raphael Szalat, MD, Subodh Kumar, PhD, Mehmet Kemal Samur, PhD, Lian Xu, Yan Xu, MD, William Senapedis, PhD, Erkan Baloglu, Stefania Oliva, MD, Masood A. Shammas, PhD, Zachary Hunter, PhD, Kenneth C Anderson, MD, Steven P Treon, MDPhDFRCP, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 648.

https://doi.org/10.1182/blood.V130.Suppl_1.648.648

Published: 2017

Journal Articles

Dysregulation of MYD88 Regulatory Isoforms in Waldenstrom's Macroglobulinemia

Amanda Kofides, BS, Maria Demos, BS, Nickolas Tsakmaklis, BA, Lian Xu, Xia Liu, MD, Guang Yang, PhD, Manit Munshi, MS, Jiaji Chen, BS, Christopher Patterson, MAcc, Maria Luisa Guerrera, MD, Jorge J. Castillo, MD, Steven P Treon, MDPhDFRCP, Zachary Hunter, PhD

Blood (2017) 130 (Supplement 1): 4967.

https://doi.org/10.1182/blood.V130.Suppl_1.4967.4967

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Somatic Variants Associated with MDS/AML Are Present in MYD88 Mutated Waldenstrom's Macroglobulinemia

Characterization of Chromosome 6q Deletions in MYD88 Mutant and Wild-Type Waldenström's Macroglobulinemia

PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Dysregulation of MYD88 Regulatory Isoforms in Waldenstrom's Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only